Additional Information

Description

Gavreto (pralsetinib) 100 mg capsules are an oral kinase inhibitor used for the treatment of specific cancers associated with RET gene alterations. It is indicated for patients with non-small cell lung cancer (NSCLC), thyroid cancer, and other RET fusion-positive solid tumors. As a targeted therapy, it selectively inhibits rearranged during transfection (RET) kinase activity, preventing cancer cell proliferation and tumor growth.

The mechanism of action involves binding to the RET kinase domain, thereby blocking downstream signaling pathways involved in tumor cell survival and progression. By inhibiting RET-driven oncogenesis, Gavreto reduces tumor burden and may enhance patient survival. The therapy is used in cases where tumors are resistant to conventional treatments or when surgery is not a viable option.

Gavreto is associated with potential adverse effects, including hypertension, hepatotoxicity, interstitial lung disease, and myelosuppression. Regular monitoring of liver enzymes, blood pressure, and complete blood counts is required to mitigate risks. Dose adjustments or treatment interruptions may be necessary if severe toxicities occur.